ArticleVirchows Archiv : an international journal of pathology2010
CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features.
Article in Virchows Archiv : an international journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Pooled it
- Pooled it
- Review
- Recent advances in understanding DNA methylation of prostate cancer.Frontiers in oncology · 2023Review
- Signature based on molecular subtypes of deoxyribonucleic acid methylation predicts overall survival in gastric cancer.World journal of gastroenterology · 2020Article
- Article
- Prognostic value of CpG island methylator phenotype in gastric cancer.Cancer science · 2018Article
- Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives.Seminars in cancer biology · 2018Review
- Genome-wide DNA methylation sequencing reveals miR-663a is a novel epimutation candidate in CIMP-high endometrial cancer.International journal of oncology · 2017Article
- ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer.Gastroenterology · 2016Article
- Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer.PloS one · 2015Article
- Methylation-mediated gene silencing as biomarkers of gastric cancer: a review.World journal of gastroenterology · 2014Review
- Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications.World journal of gastroenterology · 2014Review
- Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments.World journal of gastroenterology · 2014Review
- DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach.BMC gastroenterology · 2014Article
- The significance of epigenetic alterations in lung carcinogenesis.Molecular biology reports · 2013Review
- CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention.World journal of gastrointestinal oncology · 2012Article
- CpG island hypermethylation in gastric carcinoma and its premalignant lesions.Korean journal of pathology · 2012Article
- High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer.Cancer science · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric carcinoma (GC) is one of the human cancers in which promoter CpG island hypermethylation is frequently found. CpG island methylator phenotype (CIMP) refers to a subset of GCs which harbor concordant methylation of multiple promoter CpG island loci. However, little is known regarding clinicopathological features of CIMP-positive (CIMP-high) GC. Our study aimed to characterize clinicopathological features of CIMP-high GC. We analyzed 196 cases of GCs for their methylation status in 16 cancer-specific CpG island loci using MethyLight assay and arbitrarily defined CIMP-high GC as those with methylation at 13 or more CpG island loci. With exclusion of microsatellite instability-positive GC and EBV-positive GC from the analysis, CIMP-high GC (n = 10, 6.7%) demonstrated tendency toward higher cancer stage, infiltrative growth type, poor differentiation, and diffuse or mixed type of Lauren classification. CIMP-high GC showed significantly shortened survival compared with that of CIMP-negative GC. When CIMP-negative GC (methylation at 12 or less) was divided into CIMP-intermediate and CIMP-low (methylation at one or none), CIMP-low exhibited better clinical outcome than CIMP-intermediate. Hypermethylation at 14 CpG island loci or more was closely associated with poor clinical outcome and found to be an independent prognostic factor. Our findings that CIMP-high GCs were featured with characteristic clinicopathological parameters, including poor prognosis are distinct from previous studies. More extensive, large-scaled study is necessary to validate the findings of the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.